The 82-organ-type framework, explained.

Ageing is not one number.

Standard longevity medicine tends to compress a patient into a handful of biomarkers — a lipid panel, an HbA1c, perhaps a single biological-age score — and manage the person against that summary. Dr Oliver Zolman's insight, developed across his clinical work in longevity medicine including his role as lead doctor on Blueprint, was that this compression discards the most clinically useful information: ageing does not happen to a body uniformly. It happens organ by organ, at different rates, driven by different mechanisms, on different timelines.

A patient can have excellent cardiovascular markers and materially advanced skin and connective-tissue ageing. Another can show pristine metabolic function alongside early cognitive-domain decline that a single composite biological-age number would average away and hide. The 82-organ-type framework exists to stop that averaging from happening.

The framework is not a diagnostic gimmick layered onto existing medicine. It is a taxonomy — a way of dividing the body into 82 distinct organ types across 12 clinical domains, so that each can be assessed, tracked, and intervened upon on its own trajectory rather than folded into a single score that obscures what is actually happening underneath it.

Eighty-two organ types.

The framework — architected by Dr Oliver Zolman — divides human anatomy into 82 organ types, distributed across 12 clinical domains spanning male and female anatomy. Not every patient is assessed across all 82; the domains relevant to an individual patient's anatomy determine the actual scope, which we cover in section six. The full taxonomy:

The oral and gastrointestinal tract carries the highest organ-type count in the taxonomy, at 16 — reflecting how much distinct clinical territory sits inside a system that general medicine often manages as a single unit. The endocrine system, by contrast, is scoped at 3, not because it matters less but because Zolman's taxonomy allocates thyroid, adrenal and gonadal-axis findings with more granularity elsewhere, particularly into the reproductive and metabolic domains they drive.

Imaging, biomarkers, function.

Each domain draws on a different combination of imaging, laboratory biomarkers, and functional testing, matched to what actually reveals organ-level ageing in that system. In the nervous system domain, that means cognitive testing batteries, structural MRI where indicated, and in select cases epigenetic or proteomic markers relevant to neurodegeneration. In the cardiovascular domain, it means coronary calcium scoring, carotid intima-media thickness, lipid particle analysis, and functional cardiopulmonary testing rather than a lipid panel alone.

The musculoskeletal domain — 11 organ types, from individual joints to muscle and bone compartments — draws heavily on DEXA body composition, grip strength and functional movement testing, and targeted imaging where a specific joint or structure is in question. The oral and gastrointestinal domain, the largest in the taxonomy, combines endoscopic and stool-based findings with nutrient absorption and microbiome markers, because a single GI biomarker panel cannot represent 16 distinct organ types with materially different failure modes.

When values drift.

Intervention inside the framework follows the same logic across domains, even though the specific levers differ. When a given organ type's measurements drift outside the range expected for the patient's chronological age, that domain becomes a focus of the intervention plan — not the whole plan, but the part of it doing the most work.

In the cardiovascular domain, drift in coronary calcium trajectory or lipid particle count triggers a review of lipid-lowering strategy, exercise prescription, and in some cases pharmacological intervention. In the musculoskeletal domain, drift in DEXA-measured bone density or grip strength triggers resistance-training prescription, targeted nutrient repletion, and in appropriate cases, bone-specific pharmacotherapy. In the endocrine and reproductive domains, drift in hormonal markers triggers hormone panel review and, where clinically indicated, hormone optimisation under monitored supervision.

The through-line is that intervention is domain-specific and evidence-led. We do not apply a single supplement stack or lifestyle template across every organ type; we apply the intervention indicated by the domain's own measurements.

Organs and clocks.

The 82-organ-type framework and the multi-clock biological-age scoring Clinic82 also runs are complementary, not competing, systems. The clocks — Horvath, GrimAge, LinAge2, and the Zolman consensus score built on top of them — produce a whole-body biological age estimate from epigenetic, proteomic, and clinical-variable data. The organ-type framework then explains which specific domains are driving that number up or down.

A patient whose consensus clock reads several years older than chronological age gains little from that number alone. Read alongside the organ-type panel, the same patient's cardiovascular domain might be tracking younger than chronological age while the musculoskeletal domain is tracking meaningfully older — information the clock alone cannot supply, and information that directly determines where the intervention plan focuses. We cover the clock methodology itself in a companion protocol entry.

Not every organ, every time.

Running the full 82-organ-type assessment on every patient regardless of anatomy, history, or presenting concern would be neither useful nor proportionate. In practice, scoping follows three inputs: individual anatomy — male and female reproductive domains are scoped to the patient's relevant anatomy, not run in duplicate; clinical history — a patient with a known cardiovascular event or family history receives deeper assessment in that domain; and the patient's own stated concerns and requirements, which shape how far we extend testing into domains without an obvious clinical trigger.

This is a deliberate design choice, not a cost-driven shortcut. A framework built to give clinically actionable, organ-specific information is only useful if the testing burden on the patient is proportionate to what we expect to learn.

Still evolving.

We present the 82-organ-type framework as a rigorous taxonomy, not a finished one. Two things we are actively working through in ongoing consensus with Dr Oliver Zolman:

• Measurement standardisation across domains. Some domains — cardiovascular, musculoskeletal — have mature, widely validated measurement protocols. Others, particularly within the newer organ-type subdivisions, have measurement approaches that are still being standardised across the clinics using the framework. We flag this to patients where a given domain's assessment is less mature than another.
• Consistency of scoping decisions across clinicians. Because scoping is matched to individual anatomy and history rather than fixed, there is a real risk of inter-clinician variation in what gets tested. We are building clearer internal guidance so that two clinicians facing a similar presentation scope similarly.

The taxonomy itself — 82 organ types, 12 domains — is stable. How consistently and rigorously we measure inside it is the work still in progress.